E.L.F. Beauty’s stock is up more than 34% in the last week. The positive performance, primarily driven by an over 23% surge ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

Live Updates Live Coverage Updates appear automatically as they are published. Positive Economic Signs 11:10 am by Gerelyn ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Live Updates Live Coverage Updates appear automatically as they are published. Jamie Dimon Weighs in on Rates 12:46 pm by ...

The tech-heavy Nasdaq Composite rallied more than 9% this month. Information technology stocks are the top-performing sector ...

The company announced promising data from a pilot phase trial of its pancreatic cancer treatment, after which JonesTrading upgraded the stock to "buy" from "hold." Year-to-date, the equity is still ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...